Autres langues MacroGenics, Inc.

Actions

MGNX

US5560991094

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 13/08/2026			Varia. 5j.	Varia. 1 janv.
4,080 ^USD	+1,49%		+1,75%	+153,42%

11/08	MacroGenics et Gilead Sciences annoncent le franchissement d'une étape à 10 millions de dollars après l'exercice par Gilead de son option de licence sur un programme bispécifique préclinique	CI
23/07	MacroGenics, Inc. présente une mise à jour clinique sur l'étude de phase 1 en cours pour le MGC026	CI

Autres langues

23:06	MacroGenics: Q2 Earnings Snapshot
22:45	MacroGenics : Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position Announced sale of manufacturing operations ( July 2026) for $122.5 million and transition to fully outsourced model with leaner, approximately 140-person workforce focused on novel therapeutics pipeline Data presentations at ESMO planned for MGC026 (B7-H3 ADC) and lorigerlimab (PD-1 × CTLA-4)
22:08	MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position
11/08	MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program
11/08	Macrogenics, Inc. and Gilead Sciences, Inc. Announce Achievement of $10 Million Milestone Following Gilead Sciences, Inc.?S Exercise of Option to License Preclinical Bispecific Program
23/07	MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026
23/07	MacroGenics, Inc. Provides Clinical Update on Ongoing Phase 1 Study for MGC026
08/07	Macrogenics, Inc. Announces Resignation of Karen Ferrante from Director Role, Effective September 1, 2026
02/07	MacroGenics Closes Sale of Manufacturing Operations to Bora Pharmaceuticals
02/07	MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals ROCKVILLE, MD, July 02, 2026 (GLOBE NEWSWIRE) MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, and Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; OTCQX: BORAY), a global leader in
02/07	MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals
02/07	Bora Biologics USA, LLC completed the acquisition of Good Manufacturing Practice Drug Substance Manufacturing Operations of MacroGenics, Inc..
29/06	MacroGenics, Inc.(NasdaqGS:MGNX) added to Russell Small Cap Comp Growth Benchmark
29/06	MacroGenics, Inc.(NasdaqGS:MGNX) added to Russell 2500 Growth Benchmark
29/06	MacroGenics, Inc.(NasdaqGS:MGNX) added to Russell 2000 Index
29/06	MacroGenics, Inc.(NasdaqGS:MGNX) added to Russell 2000 Value Benchmark
29/06	MacroGenics, Inc.(NasdaqGS:MGNX) added to Russell 2000 Growth Benchmark
29/06	MacroGenics, Inc.(NasdaqGS:MGNX) added to Russell 3000E Index
29/06	MacroGenics, Inc.(NasdaqGS:MGNX) added to Russell 3000E Growth Benchmark
29/06	MacroGenics, Inc.(NasdaqGS:MGNX) added to Russell 3000E Value Benchmark
29/06	MacroGenics, Inc.(NasdaqGS:MGNX) added to Russell 2000 Dynamic Index
29/06	MacroGenics, Inc.(NasdaqGS:MGNX) added to Russell 3000 Value Benchmark
29/06	MacroGenics, Inc.(NasdaqGS:MGNX) added to Russell Small Cap Completeness Index
29/06	MacroGenics, Inc.(NasdaqGS:MGNX) added to Russell 3000 Growth Benchmark
29/06	MacroGenics, Inc.(NasdaqGS:MGNX) added to Russell 2500 Index